

INNOVATIVE MEDICINES INITIATIVE 8TH CALL

The aim of IMI is to support pre-competitive pharmaceutical research and development to foster the development of safe and more effective medicines for patients through removing identified bottlenecks in the drug development process and enhance Europe's competitiveness by ensuring that its biopharmaceutical sector remains a dynamic high technology sector.

The IMI 8th Call 2012 for proposals will have 2 topics covering the following key research priorities:

Antimicrobial resistance (two topics)
European induced pluripotent stem cell bank
Developing an aetiology-based taxonomy of human disease

Topics under consideration: Under the IMI programme Combating Antibiotic Resistance: New Drugs for Bad Bugs (ND4BB)*

Topic 1C: Innovative Trial Design & Clinical Development (work package 6 of Topic 1)

Topic 3: Discovery and development of new drugs combating Gram – negative infections

*ND4BB ('New Drugs for Bad Bugs') represents a core element of the Action plan against the rising threats from Antimicrobial Resistance adopted by the European Commission as an answer to the Council Conclusions and the European Parliament resolution to establish an EU-wide plan to combat antimicrobial resistance. The ND4BB programme started in IMI's 6th Call launched in May 2012 with two topics, and further topics are under consideration.

Other topics under consideration:

Developing an aetiology-based taxonomy of human disease
European induced pluripotent stem cell bank

Funding

For research and technological development activities, up to 75% of the eligible costs and for other activities (including management and training activities) up to 100% of the eligible costs charged to the project are eligible for funding. For the indirect costs (overheads), the legal entities eligible for funding may opt for one of the following indirect costs methods: the actual indirect costs; or the simplified method which is a modality of the actual indirect costs for organisations which do not aggregate their indirect costs at a detailed level, but can aggregate them at the level of the legal entity; or a flat rate of 20% of total eligible direct costs (excluding subcontracting costs and the costs of resources made available by third parties which are not used on the premises of the beneficiary).

Official deadline for submission of EoIs: 28 February 2013

Further Information: [Call](#)